Similar articles

• Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

  Mikhail N. Mikhail N. Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845. Expert Opin Investig Drugs. 2008. PMID: 18491986 Review.
• [The value of incretin based therapies].

  Gallwitz B. Gallwitz B. Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Dtsch Med Wochenschr. 2009. PMID: 19421931 Review. German. No abstract available.
• [Incretin-based therapy for treating patients with type 2 diabetes].

  Jermendy G. Jermendy G. Orv Hetil. 2011 Nov 27;152(48):1931-40. doi: 10.1556/OH.2011.29238. Orv Hetil. 2011. PMID: 22071295 Review. Hungarian.
• GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

  Ahrén B. Ahrén B. Curr Diab Rep. 2007 Oct;7(5):340-7. doi: 10.1007/s11892-007-0056-9. Curr Diab Rep. 2007. PMID: 18173966 Review.
• A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

  Fakhoury WK, Lereun C, Wright D. Fakhoury WK, et al. Pharmacology. 2010;86(1):44-57. doi: 10.1159/000314690. Epub 2010 Jul 12. Pharmacology. 2010. PMID: 20616619